CA2489270A1 - A method of treating human skin and a skin care composition for use in such a method - Google Patents

A method of treating human skin and a skin care composition for use in such a method Download PDF

Info

Publication number
CA2489270A1
CA2489270A1 CA002489270A CA2489270A CA2489270A1 CA 2489270 A1 CA2489270 A1 CA 2489270A1 CA 002489270 A CA002489270 A CA 002489270A CA 2489270 A CA2489270 A CA 2489270A CA 2489270 A1 CA2489270 A1 CA 2489270A1
Authority
CA
Canada
Prior art keywords
skin
composition
estrogenic component
cosmetically acceptable
acceptable vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002489270A
Other languages
French (fr)
Other versions
CA2489270C (en
Inventor
Herman Jan Tijmen Coelingh Bennink
Evert Johannes Bunschoten
Christian Franz Holinka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2489270A1 publication Critical patent/CA2489270A1/en
Application granted granted Critical
Publication of CA2489270C publication Critical patent/CA2489270C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

One aspect of the invention concerns a cosmetic method of treating human ski n by delivering an estrogenic component to said skin, the method comprising applying to the skin a composition containing: (i) at least 5 Ag/g of an estrogenic component selected from the group consisting of substances represented by the following formula (I) in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1- 5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1 , R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle. Other aspects of the invention relate to therapeutic methods of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing. Yet another aspect of the invention relates to a skin care composition comprising the aforementioned estrogenic component and a cosmetically acceptable vehicle.</ SDOAB>

Claims (16)

1. A cosmetic method of treating human skin by delivering an estrogenic component to said skin, the method comprising applying to the skin a composition containing:
(i) at least 5 µg/g of an estrogenic component selected from the group consisting of:
substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms;
precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors;
and (ii) a cosmetically acceptable vehicle.
2. Use according to claim 1, wherein R3 represents a hydroxyl group or an alkoxy group.
3. Use according to claim 1 or 2, wherein at least 3 of the groups R1, R2, R3 and R4 represent hydrogen atoms.
4. Use according to any one of claims 1-3, wherein the precursors are derivatives of the estrogenic substances wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue.
5. The cosmetic method according to any one of claims 1-4, wherein the composition is applied in an effective amount to enhance proliferation of fibroblasts and/or epidermal skin cells.
6. The cosmetic method according to any one of claims 1-5, wherein the composition is applied in an effective amount to improve skin thickness and/or skin elasticity.
7. The cosmetic method according to any one of claims 1-6, wherein the composition is applied in an effective amount to improve or prevent the condition of wrinkled, lined, dry, flaky, aged or photodamaged skin.
8. The cosmetic method according to any one of claims 1-7, wherein the composition contains at least 10 µg/g of the estrogenic component, preferably between 50 µg/g and 50 mg/g of the estrogenic component.
9. The cosmetic method according to any one of claims 1-8, wherein the composition is applied to facial skin or skin of the neck.
10. The cosmetic method according to any one of claims 1-9, wherein the composition is applied at least once a day during a period of at least 3 days.
11. The cosmetic method according to any one of claims 1-10, wherein virtually all of the composition that has been applied to the skin, is allowed to penetrate said skin.
12. Use of an estrogenic component as defined in claim 1 in the manufacture of a composition for use in a method of treating or preventing vaginal dryness, wherein the method comprises applying to the vaginal epithelium a composition containing:
(i) at least 5 µg/g of said estrogenic component; and (ii) a cosmetically acceptable vehicle.
13. Use of an estrogenic component as defined in claim 1 in the manufacture of a composition for use in a method of promoting wound healing, wherein the method comprises applying to the wounded tissue or to tissue in the vicinity of the wound a composition containing:
(i) at least 5 µg/g of said estrogenic component; and (ii) a cosmetically acceptable vehicle.
14. Use of an estrogenic component as defined in claim 1 in the manufacture of a composition for use in a method of treating or preventing acne, wherein the method comprises applying to the skin that is affected by acne or that is at risk of being affected by acne a composition containing:
(i) at least 5 µg/g of said estrogenic component; and (ii) a cosmetically acceptable vehicle.
15. A skin care composition for topical administration containing:
(i) at least 5 µg/g of an estrogenic component as defined in claim 1; and (ii) a cosmetically acceptable vehicle.
16. The skin care composition according to claim 15, which composition is a lotion, salve or a cream.
CA2489270A 2002-06-11 2003-06-11 A method of treating human skin and a skin care composition for use in such a method Expired - Lifetime CA2489270C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077273.7 2002-06-11
EP02077273 2002-06-11
PCT/NL2003/000420 WO2003103685A1 (en) 2002-06-11 2003-06-11 A method of treating human skin and a skin care composition for use in such a method

Publications (2)

Publication Number Publication Date
CA2489270A1 true CA2489270A1 (en) 2003-12-18
CA2489270C CA2489270C (en) 2012-08-07

Family

ID=29724475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2489270A Expired - Lifetime CA2489270C (en) 2002-06-11 2003-06-11 A method of treating human skin and a skin care composition for use in such a method

Country Status (7)

Country Link
US (2) US7943604B2 (en)
EP (1) EP1511498B1 (en)
CN (1) CN100352445C (en)
AU (1) AU2003274941A1 (en)
CA (1) CA2489270C (en)
ES (1) ES2399423T3 (en)
WO (1) WO2003103685A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE473746T1 (en) * 2007-01-08 2010-07-15 Pantarhei Bioscience Bv METHOD FOR TREATING OR PREVENTING INFERTILITY IN FEMALE MAMMALS AND PHARMACEUTICAL KIT FOR USING SUCH METHOD
JP2009085946A (en) 2007-09-12 2009-04-23 Kao Corp Quantification method for steroid hormone
US8924922B2 (en) * 2010-06-14 2014-12-30 Microsoft Corporation Pre-compiling hosted managed code
PT2714712T (en) 2011-06-01 2016-11-08 Estetra Sprl Process for the production of estetrol intermediates
PL2714710T3 (en) 2011-06-01 2017-03-31 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9988417B2 (en) 2013-09-18 2018-06-05 Crystal Pharma, S.A.U. Process for the preparation of estetrol
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
US10888518B2 (en) 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
MA44205B1 (en) 2015-06-18 2021-04-30 Estetra Sprl Orodispersible tablet comprising estetrol
RS60252B1 (en) 2015-06-18 2020-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (en) 2018-04-19 2019-10-19 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (en) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 Compounds and their uses for alleviating menopause-associated symptoms
HU231240B1 (en) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Industrial process for the preparation of high-purity estetrol
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2023094690A1 (en) 2021-11-29 2023-06-01 Estetra Srl Compositions for promoting hair growth
WO2023094689A1 (en) 2021-11-29 2023-06-01 Estetra Srl Compositions for preventing or treating skin aging

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2426779A1 (en) 1974-05-31 1975-12-18 Schering Ag 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity
DE2336433A1 (en) 1973-07-13 1975-04-03 Schering Ag 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity
DE2336434A1 (en) 1973-07-13 1975-04-17 Schering Ag 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (en) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd Sulfohydroxamic acid derivative, production thereof and herbicide containing the same derivative as active ingredient
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (en) 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4344405C2 (en) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Anti-ovulation agent and method for hormonal contraception
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (en) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
ATE302018T1 (en) 1997-06-20 2005-09-15 Akzo Nobel Nv GONADOTROPIN RELEASING HORMONE ANTAGONIST
DE19739916C2 (en) 1997-09-11 2001-09-13 Hesch Rolf Dieter Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (en) 1999-04-15 2000-10-19 Schering Ag Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
WO2000062753A1 (en) * 1999-04-16 2000-10-26 Jenapharm Gmbh & Co. Kg Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
AU5137900A (en) 1999-05-28 2000-12-18 University Of Cincinnati, The Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (en) 1999-10-25 2001-05-03 Laboratoire Theramex Hormonal composition based on a progestational agent and an oestrogen and use thereof
AU5984701A (en) 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
WO2002030355A2 (en) * 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy

Also Published As

Publication number Publication date
CA2489270C (en) 2012-08-07
EP1511498A1 (en) 2005-03-09
WO2003103685A1 (en) 2003-12-18
US7943604B2 (en) 2011-05-17
US20050215538A1 (en) 2005-09-29
US9040509B2 (en) 2015-05-26
CN1674915A (en) 2005-09-28
ES2399423T3 (en) 2013-04-01
AU2003274941A1 (en) 2003-12-22
US20110160173A1 (en) 2011-06-30
EP1511498B1 (en) 2012-11-21
CN100352445C (en) 2007-12-05

Similar Documents

Publication Publication Date Title
CA2489270A1 (en) A method of treating human skin and a skin care composition for use in such a method
US5629002A (en) Cosmetic or pharmaceutic preparations for improving hair quaility and stimulating growth of the hair
JP5010775B2 (en) Use of ellagic acid and its derivatives in cosmetics and dermatology
KR101678621B1 (en) Composition comprising spicules for skin care
EP1039891B1 (en) Treatment of scar tissue using lipoic acid
JPH09505836A (en) Process for the preparation of concentrated forms of biologically active silicon compounds
US20040161435A1 (en) Skin Firming Anti-Aging Cosmetic Mask Compositions
JP2002534369A (en) Topical therapeutic composition comprising N-acetylaldoseamine or N-acetylamino acid
EP2646017B1 (en) Compounds and methods for skin repair
JP2003503436A (en) Oligosaccharide aldonic acids and their topical use
JP2003505422A5 (en)
JP2005518359A (en) Compositions comprising phenyl-glycine derivatives
CA2414247C (en) Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
CN110538093A (en) polypeptide repair liquid and preparation method thereof
FR2865651B1 (en) TOPICAL COMPOSITIONS COMPRISING SODIUM HYALURONATE FRAGMENTS AND RETINOID USEFUL IN COSMETIC AND MEDICAL DERMATOLOGY
KR102534457B1 (en) Use of Topical BRaF Inhibitor Compositions for Treatment of Radiation Dermatitis
JP2022169627A (en) Methods of treating osmidrosis
KR20060014433A (en) Novel dermatological composition
JP4252444B2 (en) Use of glycoproteins for wound healing and re-epithelialization
WO2002058640A1 (en) Topical therapeutic skin care system
JPH11279080A (en) Composition for decreasing cicatrix
JPH11500730A (en) Topical treatment of scar tissue and associated tissue response to trauma
RU2004119850A (en) COMPOSITION BASED ON COMPLEX DIOSGENINE FOR TOPICAL APPLICATION
JP2001503447A (en) Compositions and methods for treating aging skin

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230612